The effects of once-weekly teriparatide on hip geometry assessed by hip structural analysis in postmenopausal osteoporotic women with high fracture risk

Bone

Volumn 64, Issue , 2014, Pages 75-81

  Sone, Teruki ^a   Ito, Masako ^b   Fukunaga, Masao ^a   Tomomitsu, Tatsushi ^c   Sugimoto, Toshitsugu ^d   Shiraki, Masataka ^e   Yoshimura, Takeshi ^f   Nakamura, Toshitaka ^g  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b NAGASAKI UNIVERSITY HOSPITAL   (Japan)

^c Kawasaki College of Allied Health Professions   (Japan)

^d SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^e RESEARCH INSTITUTE AND PRACTICE FOR INVOLUTIONAL DISEASES   (Japan)

^f ASAHI KASEI PHARMA CORPORATION   (Japan)

^g NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

Hip geometry; Hip structural analysis; Osteoporosis; Teriparatide; Weekly injection

Indexed keywords

PARATHYROID HORMONE[1-34]; PLACEBO; BONE DENSITY CONSERVATION AGENT;

AGED; AGING; ARTICLE; BONE DENSITY; BONE STRENGTH; CONTROLLED STUDY; CORTICAL THICKNESS (BONE); CROSS-SECTIONAL STUDY; DOUBLE BLIND PROCEDURE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR INTERTROCHANTERIC FRACTURE; FEMUR SHAFT FRACTURE; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PERIOSTEUM; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; FRACTURES, BONE; OSTEOPOROSIS, POSTMENOPAUSAL; PHOTON ABSORPTIOMETRY; RISK FACTOR;

ABSORPTIOMETRY, PHOTON; AGED; BONE DENSITY CONSERVATION AGENTS; FEMALE; FRACTURES, BONE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; PLACEBOS; RISK FACTORS; TERIPARATIDE;

EID: 84899136258     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2014.04.004     Document Type: Article

References (25)

1. Miyauchi A., Matsumoto T., Sugimoto T., Tsujimoto M., Warner M.R., Nakamura T. Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases. Bone 2010, 47:493-502.
2. Dempster D.W., Cosman F., Kurland E.S., Zhou H., Nieves J., Woelfert L., et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001, 16:1846-1853.
3. Hodsman A.B., Kisiel M., Adachi J.D., Fraher L.J., Watson P.H. Histomorphometric evidence for increased bone turnover and cortical thickness without increased cortical porosity after 2years of cyclical hPTH (1-34) therapy in women with severe osteoporosis. Bone 2000, 27:311-318.
4. Jiang Y., Zhao J.J., Mitlak B.H., Wang O., Genant H.K., Eriksen E.F. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003, 18:1932-1941.
5. Zanchetta J.R., Bogado C.E., Ferretti J.L., Wang O., Wilson M.G., Sato M., et al. Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 2003, 18:539-543.
6. Nakamura T., Sugimoto T., Nakano T., Kishimoto H., Ito M., Fukunaga M., et al. Randomized teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab 2012, 97:3097-3106.
7. Yoshikawa T., Turner C.H., Peacock M., Slemenda C.W., Weaver C.M., Teegarden D., et al. Geometric structure of the femoral neck measured using dual-energy X-ray absorptiometry. J Bone Miner Res 1994, 9:1053-1064.
8. Beck T.J., Ruff C.B., Warden K.E., Scott W.W., Rao G.U. Predicting femoral neck strength from bone mineral data. A structural approach. Invest Radiol 1990, 25:6-18.
9. Ahlborg H.G., Nguyen N.D., Nguyen T.V., Center J.R., Eisman J.A. Contribution of hip strength indices to hip fracture risk in elderly men and women. J Bone Miner Res 2005, 20:1820-1827.
10. Rivadeneira F., Zillikens M.C., De Laet C.E., Hofman A., Uitterlinden A.G., Beck T.J., et al. Femoral neck BMD is a strong predictor of hip fracture susceptibility in elderly men and women because it detects cortical bone instability: the Rotterdam Study. J Bone Miner Res 2007, 22:1781-1790.
11. Kaptoge S., Beck T.J., Reeve J., Stone K.L., Hillier T.A., Cauley J.A., et al. Prediction of incident hip fracture risk by femur geometry variables measured by hip structural analysis in the study of osteoporotic fractures. J Bone Miner Res 2008, 23:1892-1904.
12. LaCroix A.Z., Beck T.J., Cauley J.A., Lewis C.E., Bassford T., Jackson R., et al. Hip structural geometry and incidence of hip fracture in postmenopausal women: what does it add to conventional bone mineral density?. Osteoporos Int 2010, 21:919-929.
13. Martin R.B., Burr D.B. Non-invasive measurement of long bone cross-sectional moment of inertia by photon absorptiometry. J Biomech 1984, 17:195-201.
14. Beck T.J. Extending DXA, beyond bone mineral density: understanding hip structure analysis. Curr Osteoporos Rep 2007, 5:49-55.
15. Beck T. Measuring the structural strength of bones with dual-energy X-ray absorptiometry: principles, technical limitations, and future possibilities. Osteoporos Int 2003, 14:S81-S88.
16. Uusi-Rasi Kirsti, Semanick Lisa M., Zanchetta Jose R., Bogado Cesar E., Eriksen Erik F., Sato Masahiko, et al. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone 2005, 36:948-958.
17. Lindsay R., Zhou H., Cosman F., Nieves J., Dempster D.W., Hodsman A.B. Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Bone Miner Res 2007, 22:495-502.
18. Seeman E. Pathogenesis of bone fragility in women and men. Lancet 2002, 359:1841-1850.
19. Seeman E. Periosteal bone formation-a neglected determinant of bone strength. N Engl J Med 2003, 349:320-323.
20. Beck T.J., Oreskovic T.L., Stone K.L., Ruff C.B., Ensrud K., Nevitt M.C., et al. Structural adaptation to changing skeletal load in the progression toward hip fragility: the study of osteoporotic fractures. J Bone Miner Res 2001, 16:1108-1119.
21. Feik S.A., Thomas C.D., Bruns R., Clement J.G. Regional variations in cortical modeling in the femoral mid-shaft: sex and age differences. Am J Phys Anthropol 2000, 112:191-205.
22. Uusi-Rasia K., Semanicka L.M., Zanchettab J.R., Bogado C.E., Eriksenc E.F., Sato M., et al. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone 2005, 36:948-958.
23. Ito M., Oishi R., Fukunaga M., Sone T., Sugimoto T., Shiraki M., et al. The effects of once-weekly teriparatide on hip structure and biomechanical properties assessed by CT. Osteoporos Int 2014, 25:1163-1172.
24. Sato M., Westmore M., Ma Y.L., Schmidt A., Zeng Q.Q., Glass E.V., et al. Teriparatide [PTH(1-34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity. J Bone Miner Res 2004, 19:623-629.
25. Keaveny T.M., McClung M.R., Wan X., Kopperdahl D.L., Mitlak B.H., Krohn K. Femoral strength in osteoporotic women treated with teriparatide or alendronate. Bone 2012, 50:165-170.